News
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
Data across obesity, cardiovascular disease, MASH, type 2 diabetes ... Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio ...
Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...
Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...
Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...
Data across obesity, cardiovascular disease ... Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious ...
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and prevention ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results